An observational study in Borrelia Recurrentis Infection, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by University Hospital, Strasbourg, France · Observational
Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species.
A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.
University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Minor or adult subject having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Refusal to participate in the study
Clinical and biological description of cases of recurrent imported borreliosis
This study does not include any evaluation, but simply describes cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, and treatment.
Time frame: Up to 12 years
Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Relapsing Fever
University Hospital, Strasbourg, France →